Autolus Therapeutics AUCATZYL Q2 Revenue Surges 119%; Full-Year 2026 Outlook Raised

• Autolus Therapeutics (AUTL) reported Q2 2026 revenue surging 119% for its AUCATZYL CAR-T cell therapy, and raised its full-year 2026 revenue outlook on stronger-than-expected commercial uptake.
• AUCATZYL, approved for relapsed/refractory B-cell acute lymphoblastic leukemia, is demonstrating commercial momentum ahead of schedule as treatment centers expand their cell therapy capabilities and patient identification improves.
• The raised guidance signals Autolus management's confidence that AUCATZYL can sustain its early commercial trajectory, a critical milestone for a biotech transitioning from clinical-stage to revenue-generating operations.

Autolus Therapeutics reported a landmark second quarter for fiscal 2026, with revenue from its AUCATZYL CAR-T cell therapy surging 119% compared to the prior-year period — a growth rate that reflects both the maturation of its commercial infrastructure and expanding physician adoption across authorized treatment centers. The company also raised its full-year 2026 revenue outlook, a move that sends a strong signal to the market about the durability of AUCATZYL's commercial launch trajectory. AUCATZYL targets relapsed or refractory B-cell acute lymphoblastic leukemia, a high-unmet-need indication with limited effective options for patients who have failed prior therapies.

CAR-T therapies face notoriously challenging commercialization pathways — requiring specialized certified treatment centers, complex manufacturing logistics, and intensive patient monitoring protocols. Autolus's 119% revenue growth suggests the company is successfully navigating these structural hurdles, with a growing network of clinical sites gaining experience with AUCATZYL's administration. The expansion of treatment center certifications and the maturation of patient referral pathways typically drive accelerating commercial curves for CAR-T products, and Autolus's results indicate it is firmly on this trajectory.

The guidance raise carries significant weight for a commercial-stage biotech still consuming substantial cash to fund operations. Investors will scrutinize whether AUCATZYL's growth is driven by genuine patient demand or front-loaded center stocking, and whether gross-to-net dynamics — the difference between list price and actual realized revenue after rebates and adjustments — are tracking in line with expectations. International regulatory progress in Europe and additional label expansion opportunities will also be key catalysts. For now, the 119% revenue growth and upward guidance revision cement Autolus's credibility as a viable commercial-stage cell therapy company.